Vincristine (sulfate)

CC[C@@]1(C=CCN2CC3)[C@@]2([H])[C@@]3(C4=CC([C@](C5=C6C7=CC=CC=C7N5)(C[C@](C[C@](CC)(O)C8)([H])C[N@@]8CC6)C(OC)=O)=C(OC)C=C4N9C=O)[C@]9([H])[C@](C(OC)=O)(O)[C@@H]1OC(C)=O.O=S(O)(O)=O

[1]Jordan, M.A., et al. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res, 1985. 45 (6) : p. 2741-7.|[2]Gidding, C.E., et al, Vincristine revisited. Crit Rev Oncol Hematol, 1999. 29 (3) : p. 267-87.|[3]Donoso, J.A., et al, Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on axonal fibrillar organelles in vitro. Cancer Res, 1977. 37 (5) : p. 1401-7.|[4]Horton, J.K., et al. Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts. Biochem Pharmacol, 1988. 37 (20) : p. 3995-4000.|[5]Baguley, B.C., et al, Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer, 1991. 27 (4) : p. 482-7.|[6]Zhang D, et al. Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance. Int J Nanomedicine. 2017 Mar 16;12:2081-2108.

Acta Pharmacol Sin. 2021 Jan;42 (1) :108-114.|Acta Pharmacol Sin. 2024 Oct;45 (10) :2174-2185.|Am J Cancer Res. 2021 Apr 15;11 (4) :1428-1445.|bioRxiv. 2023 Jul 25:2023.07.23.550205.|bioRxiv. 2024 Apr 3:2023.06.02.542933.|bioRxiv. 2024 Jul 22:2023.09.14.557413.|bioRxiv. 2024 July 04.|bioRxiv. 2025 Jul 12:2025.07.08.663754.|bioRxiv. 2025 Sep 21.|Br J Cancer. 2024 Oct;131 (7) :1212-1223.|Cairo University. 2025.|Cancer Commun (Lond) . 2024 Apr;44 (4) :469-490.|Cancer Immunol Res. 2023 May 3;11 (5) :583-599.|Cancers (Basel) . 2021 Jul 2;13 (13) :3323.|Cell Biomater. 2025 Jul 22.|Cell Chem Biol. 2020 Nov 19;27 (11) :1359-1370.e8.|Cell Commun Signal. 2024 Jun 13;22 (1) :325.|Cell Death Dis. 2025 Mar 12;16 (1) :170.|Cell Rep Med. 2024 Mar 19;5 (3) :101468.|Cell Rep Med. 2025 Apr 2:102053.|Cell Rep Med. 2025 Apr 25:102098.|Cell. 2024 Apr 25;187 (9) :2288-2304.e27.|Cell. 2025 Oct 24:S0092-8674 (25) 01126-2.|Clin Epigenetics. 2025 May 6;17 (1) :77.|Drug Des Devel Ther. 2025 Feb 7:19:827-840.|Eur J Med Chem. 2018 Feb 25:146:157-170.|Front Microbiol. 2019 May 9:10:939.|Front Oncol. 2021 Apr 22:11:665763.|Front Oncol. 2021 Apr 6.|Front Oncol. 2024 Jul 19:14:1440650.|Hum Exp Toxicol. 2021 Jul;40 (7) :1208-1221.|Ind Crops Prod. 2025 Aug.|Int J Biol Macromol. 2019 May 1:128:574-582.|Int J Nanomedicine. 2017 Mar 16:12:2081-2108.|J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Apr 1:1168:122591.|J Clin Invest. 2024 Mar 7;134 (10) :e172716.|Leuk Lymphoma. 2020 Feb;61 (2) :420-428.|Leukemia. 2021 Oct;35 (10) :2827-2839.|Mol Cancer. 2024 Jan 10;23 (1) :12.|Mol Ther. 2021 Dec 1;29 (12) :3449-3464.|Neurobiol Learn Mem. 2019 Sep:163:107038.|Oncotarget. 2017 Dec 2;8 (68) :112313-112329.|Pharmacol Res. 2024 May 9:204:107208.|PLoS Biol. 2024 Jun 27;22 (6) :e3002672.|Proc Natl Acad Sci U S A. 2022 Aug 30;119 (35) :e2208457119.|Sci Adv. 2023 Feb 10;9 (6) :eade9238.|Sci Rep. 2019 Aug 12;9 (1) :11677.|SLAS Discov. 2024 Feb 12;29 (2) :100147.|SSRN. 2025 Jun 4.|Biochem Biophys Res Commun. 2023 Sep 24:674:27-35.|Biomed Pharmacother. 2020 May;125:110003.|bioRxiv. 2023 Apr 14.|bioRxiv. 2023 Feb 27:2023.02.27.530263.|bioRxiv. 2025 Aug 27.|bioRxiv. 2019 Dec.|Breast Cancer Res Treat. 2023 Jul;200 (2) :193-201.|Cancers (Basel) . 2022 Oct 19;14 (20) :5127.|Cell Mol Immunol. 2023 Jan;20 (1) :51-64.|Cell Rep Med. 2025 Oct 21;6 (10) :102401.|Clin Transl Med. 2025 May;15 (5) :e70336.|DRUG RESIST UPDATE. 2023 Feb 13;68:100951.|Front Oncol. 2020 Mar 13;10:308.|Front Pharmacol. 2022 Jul 15:13:931501.|J Biomed Inform. 2023 Jun:142:104383.|J Transl Med. 2023 Jan 9;21 (1) :9.|Mol Pharm. 2022 Nov 7;19 (11) :4320-4332.